menu
    • menu
    [{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fosfomycin Sodium","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin Sodium","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Actavis Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Actavis Inc","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Actavis Inc"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Actavis Inc \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"McNeil Consumer Health | Pfizer Inc | GSK | Chattem Chemicals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pseudoephedrine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perrigo Company plc \/ McNeil Consumer Health | Pfizer Inc | GSK | Chattem Chemicals, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Company plc \/ McNeil Consumer Health | Pfizer Inc | GSK | Chattem Chemicals, Inc"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ BARDA"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosfomycin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Meitheal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals Expands Portfolio with Acquisition of CONTEPO™ from Nabriva

                            Details : Meitheal has acquired the North American rights to CONTEPO (fosfomycin) from Nabriva. CONTEPO is a novel, intravenous, broad-spectrum antibiotic used for the treatment of urinary tract infections.

                            Product Name : Contepo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 18, 2024

                            Lead Product(s) : Fosfomycin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Meitheal Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Icon Plc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Icon Plc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV7909

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BARDA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ICON Selected By BARDA To Conduct Anthrax Vaccine Clinical Trial

                            Details : This clinical study will inform operational logistics and will not expose participants to anthrax. AV7909 is indicated for post-exposure prophylaxis of anthrax disease. Anthrax vaccine is also recommended for unvaccinated people of all ages who have been...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : AV7909

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BARDA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosfomycin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injecti...

                            Details : Nabriva received a Complete Response Letter from the U.S. FDA for the New Drug Application NDA resubmission seeking marketing approval of CONTEPO for injection for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephrit...

                            Product Name : Contepo

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2020

                            Lead Product(s) : Fosfomycin Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Actavis Inc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Endpoint Study of Ivermectin 0.5% Lotion

                            Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pediculus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 04, 2017

                            Lead Product(s) : Ivermectin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

                            Details : Lefamulin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 27, 2016

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumo...

                            Details : Lefamulin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Community-Acquired Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 24, 2015

                            Lead Product(s) : Lefamulin Acetate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Actavis Inc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalbavancin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

                            Details : Dalbavancin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteomyelitis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 26, 2015

                            Lead Product(s) : Dalbavancin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Actavis Inc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Actavis Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Labor...

                            Details : Clindamycin Phosphate is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vaginosis, Bacterial.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 07, 2014

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Actavis Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Perrigo Company plc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perrigo Company plc

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pseudoephedrine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : McNeil Consumer Health | Pfizer Inc | GSK | Chattem Chemicals, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Commo...

                            Details : Pseudoephedrine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Common Cold.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 06, 2012

                            Lead Product(s) : Pseudoephedrine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : McNeil Consumer Health | Pfizer Inc | GSK | Chattem Chemicals, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth